These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19846981)

  • 1. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer.
    Moon YW; Sohn JH; Kim YT; Chang H; Jeong JH; Lee YJ; Chang J; Kim SK; Jung M; Hong S; Choi SH; Kim JH
    Anticancer Res; 2009 Oct; 29(10):4243-9. PubMed ID: 19846981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
    Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH
    Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.
    Agelaki S; Hatzidaki D; Kotsakis A; Papakotoulas P; Polyzos A; Ziras N; Gioulbasanis I; Karampeazis A; Agelidou A; Tsiafaki X; Chandrinos V; Lerikou M; Georgoulias V
    Oncology; 2010; 78(3-4):229-36. PubMed ID: 20523083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST).
    Kawamura M; Gika M; Abiko T; Inoue Y; Oyama T; Izumi Y; Kobayashi H; Kobayashi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):507-13. PubMed ID: 16896928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
    Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
    Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Ceppi P; Novello S; Cambieri A; Longo M; Monica V; Lo Iacono M; Giaj-Levra M; Saviozzi S; Volante M; Papotti M; Scagliotti G
    Clin Cancer Res; 2009 Feb; 15(3):1039-45. PubMed ID: 19188177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
    Grossi F; Aita M; Defferrari C; Rosetti F; Brianti A; Fasola G; Vinante O; Pronzato P; Pappagallo G
    Oncologist; 2009 May; 14(5):497-510. PubMed ID: 19423674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
    Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer].
    Tanahashi M; Yamada T; Moriyama S; Suzuki E; Niwa H
    Kyobu Geka; 2008 Jan; 61(1):26-30. PubMed ID: 18186269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemosensitivity test for unresectable non-small cell lung cancer].
    Kawamura M; Inoue Y; Oyama T; Kobayashi K
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):229-32. PubMed ID: 11904985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer.
    Agteresch HJ; Leij-Halfwerk S; Van Den Berg JW; Hordijk-Luijk CH; Wilson JH; Dagnelie PC
    Clin Sci (Lond); 2000 Jun; 98(6):689-95. PubMed ID: 10814606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.
    Belani CP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S10-22. PubMed ID: 19780242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-times daily radiotherapy after chemotherapy in stage III non-small cell lung cancer. Single-institution prospective study.
    Catalano G; De Pas T; Spaggiari L; Gandini S; Jereczek-Fossa BA; De Braud F; Leo F; Veronesi G; Orecchia R
    Anticancer Res; 2008; 28(6B):4121-7. PubMed ID: 19192671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer.
    d'Amato TA; Ashrafi AS; Schuchert MJ; Alshehab DS; Seely AJ; Shamji FM; Maziak DE; Sundaresan SR; Ferson PF; Luketich JD; Landreneau RJ
    Ann Thorac Surg; 2009 Oct; 88(4):1079-85. PubMed ID: 19766784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?
    McGovern SL; Liao Z; Bucci MK; McAleer MF; Jeter MD; Chang JY; O'Reilly MS; Cox JD; Allen PK; Komaki R
    Cancer; 2009 Jul; 115(14):3233-42. PubMed ID: 19472405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.